Skip to content

Introducing Precision chemotherapy in pancreatic cancer: a phase 2 study of Panitumumab in KRAS wild-type pancreatic cancer

Share
Share

Introducing Precision chemotherapy in pancreatic cancer: a phase 2 study of Panitumumab in KRAS wild-type pancreatic cancer

11 April 2017

Monash Health hepatobiliary surgeon and interventional endoscopist Dr Daniel Croagh was awarded a Monash Partners Comprehensive Cancer Centre (MPCCC) grant worth $184,000 for his research into precision chemotherapy in pancreatic cancer.

Dr Croagh's project proposes that by using genomic sequencing of routinely obtained pancreatic cancer biopsies, it will be possible to select a small group of pancreatic cancer patients (KRAS wild-type) who potentially stand to gain substantial benefit from treatment with an EGRF inhibitor (panitumumab).

“There is a desperate need for better systemic treatments for pancreatic cancer and we are thrilled to be able to continue this research with the help of MPCCC,” said Dr Daniel Croagh.

Contact email: katherine.greenberg@monash.edu


Categories

Clinical Sciences

Tags

daniel croagh, Latest news, MPCCC